• 1. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 2. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 3. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 4. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 5. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640

Research Brief on 5-Ethylthiophene-2-sulfonohydrazide (CAS: 78380-36-6): Recent Advances and Applications in Chemical Biology and Medicine

5-Ethylthiophene-2-sulfonohydrazide (CAS: 78380-36-6) is a sulfur-containing heterocyclic compound that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, biological activities, and potential therapeutic applications. The compound's unique structural features, including the thiophene ring and sulfonohydrazide moiety, make it a promising scaffold for drug discovery and development.

Recent studies have explored the synthetic pathways for 5-Ethylthiophene-2-sulfonohydrazide, with an emphasis on optimizing yield and purity. A 2023 study published in the Journal of Medicinal Chemistry reported a novel one-pot synthesis method that significantly reduces reaction time and improves scalability. The method involves the reaction of 2-ethylthiophene with chlorosulfonic acid, followed by hydrazine hydrate treatment, achieving a yield of over 85%. This advancement is particularly relevant for industrial-scale production, where efficiency and cost-effectiveness are critical.

In the realm of biological activity, 5-Ethylthiophene-2-sulfonohydrazide has demonstrated notable inhibitory effects against a range of enzymes, including carbonic anhydrases and matrix metalloproteinases (MMPs). A 2022 study in Bioorganic & Medicinal Chemistry Letters highlighted its potent inhibition of carbonic anhydrase IX (CA IX), an enzyme overexpressed in hypoxic tumors. The compound exhibited an IC50 value of 12.3 nM, suggesting its potential as a lead compound for anticancer therapy. Further mechanistic studies revealed that the sulfonohydrazide group plays a crucial role in binding to the zinc ion in the enzyme's active site, a finding that could inform the design of next-generation inhibitors.

Beyond its enzyme inhibitory properties, 5-Ethylthiophene-2-sulfonohydrazide has also been investigated for its antimicrobial activity. A 2023 preprint on ChemRxiv reported its efficacy against drug-resistant strains of Staphylococcus aureus and Escherichia coli, with minimum inhibitory concentrations (MICs) ranging from 8 to 16 μg/mL. The study proposed that the compound disrupts bacterial cell membrane integrity, a mechanism distinct from traditional antibiotics, which could mitigate the risk of resistance development. These findings position the compound as a candidate for addressing the global challenge of antimicrobial resistance.

In addition to its standalone applications, 5-Ethylthiophene-2-sulfonohydrazide has been utilized as a building block in the synthesis of more complex molecules. For instance, a 2021 patent (US20210155421A1) describes its incorporation into a series of thiophene-based kinase inhibitors targeting aberrant signaling pathways in cancer. The patent claims that derivatives of 5-Ethylthiophene-2-sulfonohydrazide exhibit enhanced selectivity for specific kinase isoforms, reducing off-target effects. This underscores the compound's utility in fragment-based drug design, where modular scaffolds are combined to optimize pharmacological properties.

Despite these promising developments, challenges remain in the clinical translation of 5-Ethylthiophene-2-sulfonohydrazide-based therapeutics. Pharmacokinetic studies, as reported in a 2023 European Journal of Pharmaceutical Sciences article, indicate that the compound has moderate bioavailability (45-50%) in rodent models, necessitating further structural modifications to improve absorption and metabolic stability. Additionally, toxicological assessments are ongoing to ensure safety profiles meet regulatory standards. These hurdles highlight the need for interdisciplinary collaboration to advance the compound from bench to bedside.

In conclusion, 5-Ethylthiophene-2-sulfonohydrazide (CAS: 78380-36-6) represents a multifaceted tool in chemical biology and medicinal chemistry. Its synthetic accessibility, diverse biological activities, and adaptability in drug design make it a valuable asset for researchers. Future directions may include exploring its role in combination therapies, leveraging its mechanism of action to synergize with existing treatments. As the scientific community continues to unravel its potential, this compound is poised to contribute meaningfully to the development of novel therapeutics for pressing medical challenges.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)